{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T18:58:24Z","timestamp":1789844304189,"version":"4.0.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T00:00:00Z","timestamp":1765238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T00:00:00Z","timestamp":1768262400000},"content-version":"vor","delay-in-days":35,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"DOI":"10.1186\/s10194-025-02225-7","type":"journal-article","created":{"date-parts":[[2025,12,9]],"date-time":"2025-12-09T13:03:46Z","timestamp":1765285426000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["A phase 4, 24-week, open-label study to evaluate the safety and tolerability of once-daily dosing of 75\u2009mg rimegepant for episodic migraine prevention"],"prefix":"10.1186","volume":"27","author":[{"given":"Jeremias","family":"Antinew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Fountaine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio","family":"Loprinzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Straghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergey","family":"Dubrovin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"DeBesi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nick","family":"Vatakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terence","family":"Fullerton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,9]]},"reference":[{"key":"2225_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Headache Classification Committee of the International Headache Society (IHS)","year":"2018","unstructured":"Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38:1\u2013211. https:\/\/doi.org\/10.1177\/0333102417738202","journal-title":"Cephalalgia"},{"key":"2225_CR2","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s10194-020-01208-0","volume":"21","author":"TJ Steiner","year":"2020","unstructured":"Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z (2020) Migraine remains second among the world\u2019s causes of disability, and first among young women: findings from GBD2019. J Headache Pain 21:137. https:\/\/doi.org\/10.1186\/s10194-020-01208-0","journal-title":"J Headache Pain"},{"key":"2225_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/s41582-022-00763-1","volume":"19","author":"TJ Steiner","year":"2023","unstructured":"Steiner TJ, Stovner LJ (2023) Global epidemiology of migraine and its implications for public health and health policy. Nat Rev Neurol 19:109\u2013117. https:\/\/doi.org\/10.1038\/s41582-022-00763-1","journal-title":"Nat Rev Neurol"},{"key":"2225_CR4","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1111\/head.14153","volume":"61","author":"J Ailani","year":"2021","unstructured":"Ailani J, Burch RC, Robbins MS (2021) The American headache society consensus statement: update on integrating new migraine treatments into clinical practice. Headache 61:1021\u20131039. https:\/\/doi.org\/10.1111\/head.14153","journal-title":"Headache"},{"key":"2225_CR5","doi-asserted-by":"publisher","unstructured":"Silberstein SD (2015) Preventive migraine treatment. Continuum (Minneap Minn) 21:973\u2013989. https:\/\/doi.org\/10.1212\/con.0000000000000199","DOI":"10.1212\/con.0000000000000199"},{"key":"2225_CR6","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41582-018-0003-1","volume":"14","author":"L Edvinsson","year":"2018","unstructured":"Edvinsson L, Haanes KA, Warfvinge K, Krause DN (2018) Cgrp as the target of new migraine therapies - successful translation from bench to clinic. Nat Rev Neurol 14:338\u2013350. https:\/\/doi.org\/10.1038\/s41582-018-0003-1","journal-title":"Nat Rev Neurol"},{"key":"2225_CR7","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/164_2018_201","volume":"255","author":"L Edvinsson","year":"2019","unstructured":"Edvinsson L (2019) Role of cgrp in migraine. Handb Exp Pharmacol 255:121\u2013130. https:\/\/doi.org\/10.1007\/164_2018_201","journal-title":"Handb Exp Pharmacol"},{"key":"2225_CR8","unstructured":"AbbVie Inc (2019) Ubrelvy (ubrogepant) prescribing information. us food and Drug administration. https:\/\/www.rxabbvie.com\/pdf\/ubrelvy_pi.pdf. Accessed Sep 4 2024"},{"key":"2225_CR9","unstructured":"AbbVie Inc (2025) Qulipta (atogepant) prescribing information. us food and Drug administration. https:\/\/www.rxabbvie.com\/pdf\/QULIPTA_pi.pdf. Accessed Mar 25 2025"},{"key":"2225_CR10","unstructured":"Amgen Inc (2018) Aimovig (erenumab) prescribing information. us food and Drug administration. https:\/\/www.pi.amgen.com\/-\/media\/Project\/Amgen\/Repository\/pi-amgen-com\/Aimovig\/aimovig_pi_hcp_english.pdf. Accessed Sep 4 2024"},{"key":"2225_CR11","unstructured":"Eli Lilly and Company (2018) Emgality (galcanezumab-gnlm) prescribing information. us food and Drug administration. https:\/\/uspl.lilly.com\/emgality\/emgality.html#pi. Accessed Sep 4 2024"},{"key":"2225_CR12","unstructured":"Lundbeck Seattle BioPharmaceuticals Inc (2020) Vyepti (eptinezumab) prescribing information. us food and Drug administration. https:\/\/www.lundbeck.com\/content\/dam\/lundbeck-com\/americas\/united-states\/products\/neurology\/vyepti_pi_us_en.pdf. Accessed Sep 4 2024"},{"key":"2225_CR13","unstructured":"Pfizer (2025) Nurtec odt (rimegepant) prescribing information. us food and Drug administration. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19036. Accessed Jun 11 2025"},{"key":"2225_CR14","unstructured":"Pfizer Inc (2023) Zavzpret (zavegepant) prescribing information. us food and Drug administration. https:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=19471. Accessed Sep 4 2024"},{"key":"2225_CR15","unstructured":"Teva Pharmaceuticals USA Inc (2018) Ajovy (fremanezumab) prescribing information. us food and Drug administration. https:\/\/www.ajovy.com\/globalassets\/ajovy\/ajovy-pi.pdf. Accessed Sep 4 2024"},{"key":"2225_CR16","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1111\/head.14692","volume":"64","author":"AC Charles","year":"2024","unstructured":"Charles AC, Digre KB, Goadsby PJ, Robbins MS, Hershey A, The American Headache Society (2024) Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: an American headache society position statement update. Headache 64:333\u2013341. https:\/\/doi.org\/10.1111\/head.14692","journal-title":"Headache"},{"key":"2225_CR17","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/s0140-6736(19)31606-x","volume":"394","author":"R Croop","year":"2019","unstructured":"Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG et al (2019) Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet 394:737\u2013745. https:\/\/doi.org\/10.1016\/s0140-6736(19)31606-x","journal-title":"Lancet"},{"key":"2225_CR18","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/s1474-4422(23)00126-6","volume":"22","author":"S Yu","year":"2023","unstructured":"Yu S, Kim BK, Guo A, Kim MH, Zhang M, Wang Z et al (2023) Safety and efficacy of rimegepant orally disintegrating tablet for the acute treatment of migraine in China and South Korea: a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Neurol 22:476\u2013484. https:\/\/doi.org\/10.1016\/s1474-4422(23)00126-6","journal-title":"The Lancet Neurol"},{"key":"2225_CR19","doi-asserted-by":"publisher","first-page":"333102424123294","DOI":"10.1177\/03331024241232944","volume":"44","author":"R Croop","year":"2024","unstructured":"Croop R, Berman G, Kudrow D, Mullin K, Thiry A, Lovegren M et al (2024) A multicenter, open-label long-term safety study of rimegepant for the acute treatment of migraine. Cephalalgia 44:3331024241232944. https:\/\/doi.org\/10.1177\/03331024241232944","journal-title":"Cephalalgia"},{"key":"2225_CR20","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1811090","volume":"381","author":"RB Lipton","year":"2019","unstructured":"Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M et al (2019) Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med 381:142\u2013149. https:\/\/doi.org\/10.1056\/NEJMoa1811090","journal-title":"N Engl J Med"},{"key":"2225_CR21","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.2147\/jpr.S453806","volume":"17","author":"RB Lipton","year":"2024","unstructured":"Lipton RB, Thiry A, Morris BA, Croop R (2024) Efficacy and safety of rimegepant 75 mg oral tablet, a cgrp receptor antagonist, for the acute treatment of migraine: a randomized, double-blind, placebo-controlled trial. J Pain Res 17:2431\u20132441. https:\/\/doi.org\/10.2147\/jpr.S453806","journal-title":"J Pain Res"},{"key":"2225_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/s0140-6736(20)32544-7","volume":"397","author":"R Croop","year":"2021","unstructured":"Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM et al (2021) Oral rimegepant for preventive treatment of migraine: a phase 2\/3, randomised, double-blind, placebo-controlled trial. Lancet 397:51\u201360. https:\/\/doi.org\/10.1016\/s0140-6736(20)32544-7","journal-title":"Lancet"},{"key":"2225_CR23","doi-asserted-by":"publisher","unstructured":"Kitamura S, Matsumori Y, Yamamoto T, Ishikawa T, Hoshino Y, Yoshimatsu H et al (2025) Efficacy and safety of rimegepant for the preventive treatment of migraine in Japan: A double-blind, randomized controlled trial. Headache 65:1403\u20131412. https:\/\/doi.org\/10.1111\/head.14995","DOI":"10.1111\/head.14995"},{"key":"2225_CR24","first-page":"1","volume":"45","author":"PJ Goadsby","year":"2025","unstructured":"Goadsby PJ, Tassorelli C, Fountaine RJ, Antinew J, de Besi P, Dubrovin S et al (2025) Efficacy and safety of two rimegepant dosing regimens for the prevention of episodic migraine: a double-blind, placebo-controlled study [IHC25-OR-030]. Cephalalgia 45:1\u2013455","journal-title":"Cephalalgia"},{"key":"2225_CR25","doi-asserted-by":"crossref","unstructured":"Antinew J, Fountaine R, Loprinzo V, Straghan E, Fullerton T (2025) A phase 4, open-label study evaluating the safety and tolerability of Once daily rimegepant for episodic migraine prevention (P11-4.008) [meeting abstract]. Neurol 105","DOI":"10.1212\/WNL.0000000000212738"},{"key":"2225_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/head.15002","author":"D Kudrow","year":"2025","unstructured":"Kudrow D, Croop RS, Thiry A, Lipton RB (2025) A 52-week open-label extension study to evaluate the safety and efficacy of oral rimegepant for the preventive treatment of migraine. Headache. [Epub ahead of print]. https:\/\/doi.org\/10.1111\/head.15002","journal-title":"Headache"},{"key":"2225_CR27","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s40120-023-00562-w","volume":"13","author":"TJ Schwedt","year":"2024","unstructured":"Schwedt TJ, Myers Oakes TM, Martinez JM, Vargas BB, Pandey H, Pearlman EM et al (2024) Comparing the efficacy and safety of galcanezumab versus rimegepant for prevention of episodic migraine: results from a randomized, controlled clinical trial. Neurol Ther 13:85\u2013105. https:\/\/doi.org\/10.1007\/s40120-023-00562-w","journal-title":"Neurol Ther"},{"key":"2225_CR28","doi-asserted-by":"publisher","first-page":"820006","DOI":"10.3389\/fphys.2021.820006","volume":"12","author":"P Holzer","year":"2021","unstructured":"Holzer P, Holzer-Petsche U (2021) Constipation caused by anti-calcitonin gene-related peptide migraine therapeutics explained by antagonism of calcitonin gene-related peptide\u2019s motor-stimulating and prosecretory function in the intestine. Front Physiol 12:820006. https:\/\/doi.org\/10.3389\/fphys.2021.820006","journal-title":"Front Physiol"},{"key":"2225_CR29","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1111\/head.13956","volume":"60","author":"A Alex","year":"2020","unstructured":"Alex A, Vaughn C, Rayhill M (2020) Safety and tolerability of 3 cgrp monoclonal antibodies in practice: a retrospective cohort study. Headache 60:2454\u20132462. https:\/\/doi.org\/10.1111\/head.13956","journal-title":"Headache"},{"key":"2225_CR30","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1007\/s00415-021-10523-8","volume":"268","author":"M Torres-Ferr\u00fas","year":"2021","unstructured":"Torres-Ferr\u00fas M, Gallardo VJ, Alpuente A, Caronna E, Gine-Cipres E, Pozo-Rosich P (2021) The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study. J Neurol 268:3789\u20133798. https:\/\/doi.org\/10.1007\/s00415-021-10523-8","journal-title":"J Neurol"},{"key":"2225_CR31","doi-asserted-by":"publisher","first-page":"251581632412923","DOI":"10.1177\/25158163241292307","volume":"7","author":"S Uzun","year":"2024","unstructured":"Uzun S, Frejvall U, Petersson P, Sahin G (2024) Constipation as a possible predictor of poor treatment response in chronic migraine: a retrospective study of anti-calcitonin gene-related peptide (anti-CGRP) monoclonal antibodies and the impact of switching. Cephalalgia Rep 7:25158163241292307. https:\/\/doi.org\/10.1177\/25158163241292307","journal-title":"Cephalalgia Rep"},{"key":"2225_CR32","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1186\/s10194-025-02087-z","volume":"26","author":"FM Amin","year":"2025","unstructured":"Amin FM, Linnet T, Cullum CK, Do TP, Younis S (2025) Tolerability of switch from erenumab to fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, real-world, observational study. J Headache Pain 26:152. https:\/\/doi.org\/10.1186\/s10194-025-02087-z","journal-title":"J Headache Pain"},{"key":"2225_CR33","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/head.14062","volume":"61","author":"CC Chiang","year":"2021","unstructured":"Chiang CC, Arca KN, Dunn RB, Girardo ME, Quillen JK, Dodick DW et al (2021) Real-world efficacy, tolerability, and safety of ubrogepant. Headache 61:620\u2013627. https:\/\/doi.org\/10.1111\/head.14062","journal-title":"Headache"},{"key":"2225_CR34","doi-asserted-by":"publisher","first-page":"e1897","DOI":"10.1212\/wnl.0000000000201008","volume":"99","author":"S de Vries Lentsch","year":"2022","unstructured":"de Vries Lentsch S, van der Arend Bwh, Maassen VanDenbrink A, Terwindt GM (2022) Blood pressure in patients with migraine treated with monoclonal anti-CGRP (receptor) antibodies: a prospective follow-up study. Neurology 99:e1897\u2013e1904. https:\/\/doi.org\/10.1212\/wnl.0000000000201008","journal-title":"Neurology"},{"key":"2225_CR35","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/head.14051","volume":"61","author":"S Saely","year":"2021","unstructured":"Saely S, Croteau D, Jawidzik L, Brinker A, Kortepeter C (2021) Hypertension: a new safety risk for patients treated with erenumab. Headache 61:202\u2013208. https:\/\/doi.org\/10.1111\/head.14051","journal-title":"Headache"},{"key":"2225_CR36","doi-asserted-by":"publisher","first-page":"5675","DOI":"10.1038\/s41598-025-87421-w","volume":"15","author":"N Lee","year":"2025","unstructured":"Lee N, Ok JH, S-J R, Kim Y (2025) Disproportionality analysis of Raynaud\u2019s phenomenon associated with calcitonin gene-related peptide inhibitors using the food and Drug administration adverse event reporting system. Sci Rep 15:5675. https:\/\/doi.org\/10.1038\/s41598-025-87421-w","journal-title":"Sci Rep"},{"key":"2225_CR37","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1186\/s10194-024-01925-w","volume":"25","author":"L Pellesi","year":"2024","unstructured":"Pellesi L, Garcia-Azorin D, Rubio-Beltr\u00e1n E, Ha W-S, Messina R, Ornello R et al (2024) Combining treatments for migraine prophylaxis: the state-of-the-art. J Headache Pain 25:214. https:\/\/doi.org\/10.1186\/s10194-024-01925-w","journal-title":"J Headache Pain"},{"key":"2225_CR38","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s10194-025-02028-w","volume":"26","author":"L Pellesi","year":"2025","unstructured":"Pellesi L, Do TP, Ernst MT, Hallas J, Potteg\u00e5rd A (2025) Adoption of rimegepant in Denmark: a register-based study on uptake, prescribing patterns and initiator characteristics. J Headache Pain 26:83. https:\/\/doi.org\/10.1186\/s10194-025-02028-w","journal-title":"J Headache Pain"},{"key":"2225_CR39","doi-asserted-by":"publisher","first-page":"333102425135284","DOI":"10.1177\/03331024251352849","volume":"45","author":"SJ Tepper","year":"2025","unstructured":"Tepper SJ, Jenkins A, Henriksen C, Dai F, Atkinson J, Abraham L et al (2025) A comparison of the persistence of acute treatment with rimegepant versus oral triptans in patients with migraine: a retrospective analysis of us claims data. Cephalalgia 45:3331024251352849. https:\/\/doi.org\/10.1177\/03331024251352849","journal-title":"Cephalalgia"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02225-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-025-02225-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-025-02225-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T03:03:42Z","timestamp":1768359822000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s10194-025-02225-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,9]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2225"],"URL":"https:\/\/doi.org\/10.1186\/s10194-025-02225-7","relation":{},"ISSN":["1129-2377"],"issn-type":[{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,9]]},"assertion":[{"value":"8 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Advarra Institutional review Board (Columbia, MD). All participants provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JA, RJF, VL, ES, SD, PD, and TF are (or were at the time of the study) employees of, and own stock\/options in, Pfizer. NV has no competing interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"17"}}